

1 **Personalized external aortic root support for elective** 2 **treatment of aortic root dilation in 200 patients**

3
4
5 Lucas Van Hoof MD
6 Resident General Surgery, PhD Student Cardiac Surgery
7 Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium

8
9 Filip Rega MD PhD
10 Professor of Surgery, Cardiac Surgeon
11 Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium

12
13 Tal Golesworthy C Eng MEI MRSC
14 Technical Director
15 Exstent Ltd., Tewkesbury, UK

16
17 Peter Verbrugge MD PhD
18 Professor of Surgery, Cardiac Surgeon
19 Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium

20
21 Conal Austin MB BCh FRCS(Ed) FRCSI FRCS CTh
22 Consultant Cardiac Surgeon
23 Department of Paediatric Cardiology and Cardiothoracic Surgery, St. Thomas' Hospital, London, UK

24
25 Johanna JM Takkenberg MD PhD
26 Professor of Cardiovascular Epidemiology
27 Erasmus University Medical Centre, Rotterdam, Netherlands.

28
29 John Pepper MD MChir FRCS FESC
30 Consultant Cardiac Surgeon
31 Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London, UK
32 National Heart and Lung Institute, Imperial College London, London, UK
33 NIHR Imperial Biomedical Research Centre, London, UK

34
35 Tom Treasure MS MD FRCS FRCP
36 Honorary Professor of Cardiothoracic Surgery
37 Clinical Operational Research Unit, University College London, London, UK

40 41 **The corresponding author**

42 Lucas Van Hoof, MD
43 Department of Cardiac Surgery, University Hospitals Leuven
44 Herestraat 49, 3000 Leuven, Belgium
45 lucas.vanhoof@kuleuven.be
46 Tel: + 32 495/851048 or +32 16/344260
47 Fax : +32 16/344616

48
49 **Word count: 3216**

50 **Abstract**

51 **Background and objectives**

52 In Personalised External Aortic Root Support (PEARS) a custom-made, macroporous mesh is used to stabilise a
53 dilated aortic root and prevent dissection, primarily in patients with genetically driven aortopathies. Data are needed
54 on the safety and postoperative incidence of aortic events.

55 **Methods**

56 We present a multicentre cohort study evaluating the first 200 consecutive patients (median age 33y) undergoing
57 surgery with an intention to perform PEARS for aortic root dilatation in 23 centres between 2004-2019.
58 Perioperative outcomes were collected prospectively while clinical follow-up was retrieved retrospectively. Median
59 follow-up was 21.2 months.

60
61 **Results**

62 The main indication was Marfan syndrome (73.5%) and the most frequent concomitant procedure was mitral valve
63 repair (10%). An intervention for myocardial ischemia or coronary injury was needed in 11 patients, 1 case resulting
64 in perioperative death. No ascending aortic dissections were observed in 596 documented postoperative patient
65 years. Late reoperation was performed in 3 patients for operator failure to achieve complete mesh coverage. Among
66 patients with at least mild AR preoperatively, 68% had no or trivial AR at follow-up.

67
68 **Conclusions**

69 This study represents the clinical history of the first 200 patients to undergo PEARS. To date, aortic dissection has
70 not been seen in the restrained part of the aorta, yet long-term follow-up is needed to confirm the potential of
71 PEARS to prevent dissection. While operative mortality is low, the observed coronary complications reflect the
72 learning curve of aortic root surgery in patients with connective tissue disease. PEARS may stabilise or reduce aortic
73 regurgitation.

74
75
76 **Keywords**

77 Aortic aneurysm, Marfan syndrome, pre-emptive, personalised, mesh, aortic dissection

78
79 **Abbreviations**

80 CABG=coronary artery bypass grafting
81 CPB=cardiopulmonary bypass
82 PEARS = personalised external aortic root support
83 TRR = total root replacement
84 VSRR = valve sparing root replacement
85 MFS = Marfan syndrome
86 IQR = interquartile range
87 AR = aortic regurgitation (or aortic insufficiency)

88 **Key questions**

89 – **What is already known about this subject?**

90 Personalised External Aortic Root Support (PEARS) stabilises aortic root dimensions and has been used primarily in
91 patients with genetically driven aortopathies. The ExoVasc implant becomes incorporated at a cellular level and
92 reduces wall stress.

93

94 – **What does this study add?**

95 This study represents the clinical history of a new surgical technique from patient 1 to 200, including the learning
96 curve while surgical indications expand and the procedure is implemented at an increasing number of centres
97 worldwide. No ascending aortic dissections were observed in 596 postoperative patient years. While operative
98 mortality is low, the observed coronary complications reflect the learning curve of aortic root surgery in patients
99 with connective tissue disease.

100

101 – **How might this impact on clinical practice?**

102 As PEARS preserves the native aorta, earlier intervention in the disease progression can be justified. This suggests
103 that the diameter cut-off values in current guidelines on the surgical management of aortic root aneurysm do not
104 accommodate many patients who may be eligible for PEARS. PEARS stabilises or even reduces AR, adding to its
105 pre-emptive value and justifying the application in patients with mild AR.

106

107

108 **INTRODUCTION**

109 Genetically determined aortic root aneurysms are conventionally treated by pre-emptive aortic root
110 replacement at a threshold size judged to minimise the balance of risk between proceeding and deferring
111 operation.[1] Total root replacement (TRR) with a mechanical or biological valved conduit does not
112 completely restore the life-expectancy of these patients, typically under 50 years old at time of
113 surgery.[2,3] A mechanical valve exposes patients to lifelong anticoagulant therapy and risks of thrombo-
114 embolism or bleeding while the likelihood of biological valve failure in young patients remains a
115 concern.[2,4] Although the haemodynamic outcome of valve sparing root replacement (VSRR) is superior
116 and anticoagulation is avoided, it remains a technically demanding procedure with a risk of
117 reoperation.[3] Personalised External Aortic Root Support (PEARS) is a pre-emptive, total tissue-sparing
118 alternative whereby a custom-made, macroporous mesh (ExoVasc®) is used to stabilise the aortic root
119 and ascending aorta (Figure 1). The first 30 cases were reported in Heart in 2014.[5] A descriptive report
120 of a consecutive series of 117 patients with at least two year follow up was published in 2020.[6]

121 The principal indication has been a moderately dilated aortic root (40-50mm) with at most mild aortic
122 regurgitation (AR), primarily in patients with Marfan syndrome (MFS) and other genetically driven
123 aortopathies. Technical details of the manufacturing process, surgical procedure and early outcomes have
124 been systematically reported.[5–7] PEARS has the potential to eliminate the risk of aortic dissection by
125 augmenting the mechanical properties of a compromised aortic wall while reducing circumferential and
126 longitudinal wall stress.[5,8–13]

127 To confirm the ability of PEARS to prevent aortic dissection, the long-term incidence of aortic and
128 device-related events must be followed. The aim of this study is to report clinical outcomes for the first
129 200 primary aortic PEARS cases as the procedure was implemented at an increasing number of centres
130 worldwide.

131

132 **METHODS**

133 **Study design**

134 We present a retrospective multicentre cohort study evaluating all consecutive patients undergoing
135 surgery with an intention to perform PEARS for aortic root dilatation between May 2004 and June 2019.
136 The study protocol was approved by the Ethical Committee of the University Hospitals Leuven (S63787)
137 as the majority of data analysis took place at this centre. The need for further patient consent was waived.

138 **Data collection**

139 For all procedures, a case report form was returned to Exstent Ltd, ensuring that patient demographics,
140 operative characteristics and in-hospital outcomes were collected prospectively. The recorded aortic root
141 size is the largest diameter at the level of aortic leaflet coaptation, measured on the MRI or CT scan used
142 to manufacture the implant. These data were stored securely on a server at Exstent Ltd. in accordance
143 with local regulations and anonymised prior to further data collection. For the purpose of this study,
144 surgeons were contacted and asked to provide detailed demographics, in-hospital outcomes and clinical
145 follow-up data via anonymised spreadsheets (Supplementary material online, Table S2). Data collection
146 commenced in October 2019 and was finalised in August 2020.

147 **Data analysis**

148 Follow-up completeness was defined as the follow-up index for the entire study population, calculated by
149 dividing “documented postoperative patient years” by “optimal follow-up”.[14] The date representing
150 optimal follow-up for each patient was defined by when follow-up data was returned, or when the patient
151 died. As such, discrepancies between optimal and documented follow-up years may be related to (a) the
152 interval between last clinical follow-up and when data was returned for a patient (b) patient lost to follow-
153 up or died without the researchers being aware. Continuous variables were reported as median
154 (interquartile range (IQR), range) or mean \pm SD, categorical variables as n (%). Comparison of
155 continuous variables between subgroups was performed using the Mann–Whitney *U* test, categorical data

156 were compared using the chi-squared test. To estimate survival and survival free from reoperation, a
157 Kaplan-Meier analysis was performed.

158 The effect of PEARS on AR was evaluated by comparing preoperative AR grade with immediate
159 postoperative AR recorded by the surgeon and with the independent recording of valve function during
160 follow-up. For the analysis of AR evolution, patients reported to have no or trivial AR preoperatively
161 (grade 0/4 or 0.5/4) were distinguished from patients reported to have at least mild AR (grade $\geq 1/4$).
162 Patients who previously underwent aortic valve replacement or who did not receive the ExoVasc implant
163 were excluded. A logistic mixed effects model was used to evaluate the change in probability of having at
164 least mild AR over time during follow-up. Random intercepts were used to capture the correlation of the
165 repeated measurements in patients. Data analysis was performed using Microsoft Office Excel 2016
166 (Microsoft), Prism (GraphPad Software) and RStudio (RStudio, PBC).

167 **Patient and public involvement**

168 Tal Golesworthy is the inventor of the ExoVasc device and was the first patient to undergo PEARS in
169 2004. No other patients were involved in the design, conduct or reporting of this study.

170

171

172 **RESULTS**

173 Between May 2004 and June 2019, 200 patients underwent surgery with the intention to perform PEARS
174 for primary aortic root dilatation. The operations were performed by 27 surgeons in 23 centres. The
175 number of operations per surgeon ranged from 1 to 45 (median 3, IQR 1-9). The majority of cases
176 (119/200, 59.5%) were performed in 2017, 2018 or 2019 (Supplementary material online, Figure S1).

177 There was an expansion in the number of surgeons joining so there was a disproportionate number with,
178 as yet, few operations performed.

Variable	Total population (n=200)
Male	138 (69)
Age (y)	33 (23-45; 3-75)
Height (cm)	185 (178-193; 107-206)
Root diameter (mm)	47 (44-49; 28-60)
Surgical indication	
Marfan syndrome	147 (73.5)
BAV	17 (8.5)
Loeys-Dietz syndrome	15 (7.5)
ACTA2 mutation	2 (1)
Idiopathic/other	19 (9.5)
Previous cardiac surgery	8 (4)
Mechanical AVR	2 (1)
MV repair	2 (1)
Coarctation repair	2 (1)
Fallot tetralogy repair	1 (0.5)
VSD closure	1 (0.5)
Preop AR grade*	
0/4	130 (65)
0.5/4	17 (8.5)
1/4	45 (22.5)
2/4	6 (3)
LVEF (%)	60 (57-64; 40-72)
LVEDD (mm)	52 (46-56; 31-68)

179 **Table 1.** Demographic characteristics of the first 200 patients to undergo primary aortic PEARS.
180 Categorical variables shown as n (%), continuous variables shown as median (IQR; range). *n=198 as 2
181 patients with history of aortic valve replacement (AVR) are excluded. AR= aortic regurgitation,
182 BAV=bicuspid aortic valve, LVEF=left ventricular ejection fraction, LVEDD=left ventricular end-
183 diastolic diameter, MV=mitral valve, VSD=ventricular septum defect.

184

185 **Patient demographics and operative characteristics**

186 For the 147 patients with MFS, median root diameter was 47mm whereas for patients with Loeys-Dietz
187 syndrome or a bicuspid aortic valve, it was 42mm and 48mm, respectively. 11 patients had a root
188 diameter <40mm and either had Loeys-Dietz syndrome, an aggressive manifestation of MFS or a primary
189 indication for mitral valve repair with PEARS performed concomitantly. Similarly, the 19 children in this
190 cohort underwent concomitant mitral valve repair or had a malignant phenotype, the youngest patient a 3
191 year old girl with a root diameter of 38.4mm. Conversely, those patients with a root diameter \geq 55mm
192 (n=8) or above 65 years old (n=7), had an explicit preference for PEARS or an indication for concomitant

193 CABG. The demographic characteristics of the described population are shown in Table 1, the
194 distribution of patient age and preoperative aortic root diameter in the Supplementary material online,
195 Figure S2-3. 194 patients received the ExoVasc implant (Figure 2). For 166 isolated aortic PEARS cases,
196 cardiopulmonary bypass (CPB) was used in 21.1%. A full overview of operative characteristics and
197 concomitant procedures is shown in Table 2.

198 **Perioperative adverse events**

199 In 1 patient with MFS and a severe pectus deformity, the left main stem was injured. The case has already
200 been reported.[15] This patient, in whom the ExoVasc was not implanted, represents the only early death
201 in this study, resulting in a 0.5% perioperative mortality.

202 An intraoperative conversion (TRR n=2; VSRR n=3) was performed in 5 patients in whom the surgeon
203 judged that the fragility of the aorta was a contra-indication to PEARS (n=3) or after coronary injury
204 (n=2). An intra- or postoperative intervention was carried out in 11 patients (5.5%) for myocardial
205 ischemia or coronary complications (Table 2). The indications were coronary impingement caused by the
206 implant (n=2) or coronary injury (n=6). In 3 patients who received an ExoVasc, the adverse event was not
207 caused by the implant or implantation thereof (Supplementary material online, Table S1 for additional
208 details). Five of these patients (2.5%) suffered a myocardial infarction with repercussions on ventricular
209 function. There was one limited intraoperative aortic dissection during an isolated PEARS procedure,
210 related to aortic cannulation. The dissection was treated conservatively and was stable on postoperative
211 imaging. Postoperatively, 2 patients developed a cerebrovascular event with hemiparesis, attributed to
212 atrial fibrillation after off-pump PEARS. Both patients recovered completely. There were no revisions for
213 bleeding.

214

215

In-hospital outcome for 200 procedures with intention to perform PEARS	
PEARS completed	194 (97)
Isolated aortic PEARS	166 (83)
PEARS + mitral valve repair	20 (10)
PEARS + elective OPCAB	3 (1.5)
PEARS + mitral valve replacement	1 (0.5)
PEARS + pulmonary homograft	1 (0.5)
PEARS + PFO closure	1 (0.5)
PEARS + pectus repair	1 (0.5)
PEARS from aortic annulus to distal arch	1 (0.5)
Converted to VSRR	3 (1.5)
Converted to TRR	2 (1)
Procedure aborted *	1 (0.5)
Implant size (n=194)	
95%	106 (54.6)
100%	88 (45.4)
Completed PEARS procedures (n=194)	
Operative duration (min)	183 ± 65
Isolated aortic PEARS (n=166)	
Operative duration (min)	174 ± 51
CPB used	35 (21.1)
CPB time (min)	62 ± 24
Length of stay (d) (n=194)	6 (5-7)
Adverse events	
Perioperative mortality *	1 (0.5)
Intervention for ischemia or coronary injury	11 (5.5)
CABG	6 (3)
CABG + PCI	1 (0.5)
CABG + IABP	1 (0.5)
CABG + VA-ECMO *	1 (0.5)
IABP	1 (0.5)
Revision to release tension on implant	1 (0.5)
Myocardial infarction	5 (2.5)
Intraoperative aortic dissection	1 (0.5)
Cerebrovascular event	2 (1)

216
217 **Table 2.** Operative characteristics and adverse events for all patients undergoing surgery with the
218 intention to perform PEARS. *This is the same patient. Categorical variables shown as n (%), continuous
219 variables shown as mean ± SD or median (IQR). CABG=coronary artery bypass grafting,
220 CPB=cardiopulmonary bypass, IABP=intra-aortic balloon pump, OPCAB=off-pump coronary artery
221 bypass grafting, PCI=percutaneous coronary intervention, PFO=patent foramen ovale, TRR=total root
222 replacement, VA-ECMO=veno-arterial extracorporeal membrane oxygenation, VSRR=valve-sparing root
223 replacement.
224

225

226

227 **Clinical follow-up**

228 Optimal clinical follow-up for the 200 patients corresponded to 753 postoperative patient years. In this
229 study, 603 years were documented, representing 80% follow-up completeness calculated according to the
230 follow-up index.[14] Median follow-up duration was 21.2 months (IQR 10-44.1, range 0-190.5) and
231 clinical follow-up beyond 12 months was available for 142/197 (72.1%). One patient had documented
232 follow-up beyond 15 years, 13 patients beyond 10 years and 34 patients beyond 5 years. Among the 194
233 patients who received the ExoVasc implant, 596 postoperative patient years were documented. For 2
234 patients who received the implant and had travelled overseas to undergo surgery, no follow-up could be
235 obtained, amounting to 6 lost follow-up years. For 1 patient in whom a conversion to TRR was
236 performed, no follow-up could be obtained (Figure 2), amounting to 1.3 lost follow-up years.

237 **Aortic events**

238 No ascending aortic dissections were observed. In 1 asymptomatic patient, a new type B dissection was
239 discovered on imaging 3 years postoperatively. No device-related aortic events occurred, nor were there
240 any late thrombo-embolic or bleeding events. Nine female patients had one or more successful
241 pregnancies without cardiovascular complications after undergoing PEARS surgery.

242 A late reoperation was performed in 3 patients for failure to achieve complete coverage by the ExoVasc
243 implant. In 1 patient, the implant had been cut off at the level of the coronaries contrary to the operation
244 protocol, resulting in proximal dilatation and progressive AR.[16] At 39 months postoperatively, his root
245 was reduced down to its original size and supported by a new implant. In another patient, right ventricular
246 stunning occurred postoperatively and the implant was partially reopened. She underwent uncomplicated
247 revision surgery (bioprosthetic root replacement) 6 years later and was well at 10 year follow-up. In the
248 third patient, the opening for the right coronary artery was larger than required. At reoperation 9.5 years
249 postoperatively, a local dilatation was resected and the coronary artery reimplanted. She remains well
250 11.4 years postoperatively.

251 **Survival**

252 Among patients who received the ExoVasc implant, there were 4 late deaths. One patient, with a history
253 of aortic valve replacement, a flow-limiting lesion in the left circumflex artery and alcoholic
254 cardiomyopathy for which he had an implantable cardioverter-defibrillator (ICD), was offered PEARS
255 because he was deemed unfit for root replacement. He suffered circumflex artery occlusion
256 postoperatively, unrelated to PEARS, for which surgical revascularisation was performed. He was
257 discharged home with systolic heart failure and died 7 months postoperatively unrelated to PEARS. One
258 patient died 14 months postoperatively from an unknown cause. The two other deaths were unrelated to
259 PEARS: 1 patient died 3 years postoperatively due to COVID-19 and the other died in his sleep 4.5 years
260 postoperatively. At post mortem his aortic valve was competent and coronary arteries healthy and
261 unimpeded, as previously reported.[11] The three patients converted to VSRR were well at 13, 27 and 32
262 months follow-up, respectively. The patient who had TRR after coronary injury died 5 months
263 postoperatively, attributed to an arrhythmia. No follow-up could be obtained for 1 remaining patient who
264 underwent TRR. The Kaplan-Meier estimate for survival and survival free from reoperation for all
265 patients undergoing surgery with the intention to perform PEARS, while also including the 1
266 perioperative death, is shown in Figure 3.

267 **Aortic regurgitation**

268 AR grade was recorded preoperatively and immediately postoperatively for all patients. For 80.2%
269 (154/192) of patients who received the ExoVasc implant, AR grade was documented at one time point at
270 least 2 weeks postoperatively (median 24.1 months). For patients with no or trivial AR preoperatively
271 (74.2%, 147/198), the postoperative changes in AR were limited and deemed unlikely to be clinically
272 significant. Sankey diagrams depicting the evolution in AR grade between measurement points are
273 included in the Supplementary material online, Figures S4-8.

274 Patients with AR \geq 1/4 at the time of PEARS (n=48) were significantly older (median 40 vs 32 years,
275 p=0.025) and had a larger root diameter (48 vs 46 mm, p=0.002) than patients with no or trivial AR.

276 Immediately after PEARS, 42% (20/48) had a reduction in AR grade of at least 1 point, such that 63%
277 (30/48) had no or trivial AR postoperatively (Supplementary material online, Figure S6 and S9A).

278 Among patients receiving an ExoVasc implant scaled to 95% luminal diameter, a significantly greater
279 proportion had no or trivial AR postoperatively compared to patients receiving a 100% implant (77%,
280 23/30 vs 39%, 7/18, $p=0.009$).

281 For patients with preoperative AR $\geq 1/4$ and a follow-up echocardiography ($n=37$), 54% (20/37) had a
282 reduction in AR grade of at least 1 point compared to preoperatively. At follow-up (median 22.3 months),
283 68% (25/37) of patients had no or trivial AR (Supplementary material online, Figure S7 and S9A). While
284 not significant, patients receiving a 95% implant were more likely to have no or trivial AR at follow-up
285 than patients receiving a 100% implant (75%, 15/20 vs 59%, 10/17, $p=0.3$) (Supplementary material
286 online, Figure S9B and S9C).

287 Figure 4 illustrates the evolution in AR grade per patient between different measurement points, with
288 patients with AR grades 0 and 0.5 combined into one group. There were no statistically significant
289 differences with regards to preoperative AR grade, aortic root diameter, age or implant size between
290 patients who did or did not have at least a 1 point reduction in AR grade when comparing any of the 3
291 time points. In a logistic mixed effects model, there was no change in the probability of having at least
292 mild AR over time (OR:0.97 95% CI [0.93-1.02], $p=0.213$) between the postoperative and follow-up
293 echocardiography.

294 **DISCUSSION**

295 This study represents the clinical history of the first 200 consecutive patients to have personalised
296 external aortic root support (PEARS) for aortic root aneurysm, from the 1st patient onwards. With follow-
297 up beyond 1 year available for 72.1% and median follow-up of 21.2 months, this is the most extensive
298 report on PEARS to date.

299 From the outset we explored the possibility of a controlled trial but advice at the highest level of research
300 methodology was that the different inclusion criteria and cogent patient preferences about timing of
301 intervention and avoidance of anticoagulation precluded equipoise.[15,17] A recent independent expert
302 analysis of the question reached the same conclusion.[18]

303 In the absence of a direct randomised comparison, we refer to available data on root replacement. In the
304 multicentre AVIATOR registry including 4896 patients in expert centres, the perioperative mortality after
305 VSRR and TRR was 1.2% and 2% respectively. Among 200 patients in this report there was one
306 perioperative death (0.5%). In a meta-analysis of TRR and VSRR for root aneurysm in MFS, the annual
307 rate of major bleeding was 1.3% and 0.1%, of thrombo-embolism was 0.7% and 0.4%, with reoperation
308 rates of 1.3% and 0.6% respectively.[3] The cumulative burden of these complications during 603
309 postoperative years would be considerable. PEARS completely preserves the blood-endothelial interface
310 and there were no late thromboembolic or bleeding events. There were 3 late reoperations, each
311 attributable to failure to achieve the intended complete coverage of the ascending aorta, all errors
312 avoidable with greater experience.[16]

313 In making these comparisons we recognise that the 200 PEARS patients were mainly young, low risk
314 patients with predominantly normal aortic valve function. In large series of root replacement in patients
315 with MFS, median preoperative root diameter was 48-54mm for VSRR and 54-55mm for TRR as
316 compared to 47mm in our study.[19–21] We are also mindful that in reported series, the cases are
317 categorised on the basis of the operations as completed. So if VSRR proves difficult to achieve, the

318 default is to resort to TRR, thus favouring the results for valve sparing surgery. We chose to report results
319 according to intention to treat.

320 The effectiveness of PEARS must be measured by its ability to prevent ascending aortic dissection,
321 historically the main cause of morbidity and mortality in patients with genetic aortopathies.[22,23] The
322 absence of type A dissections in our study is consistent with previous reports showing that PEARS
323 stabilises aortic dimensions while becoming incorporated histologically and reducing wall stress.[5,8–13]
324 It is unknown how many dissections were effectively prevented in our study as it is currently not possible
325 to predict who would have dissected without surgery.[24] Because many patients were operated at an
326 earlier disease stage than at which root replacement is typically performed, and because follow-up is short
327 for many patients, long-term follow-up is needed to monitor the occurrence of aortic events.[25]

328 Positioning the implant around the coronary artery origins, typically on a beating heart, is challenging and
329 one of the main technical pitfalls of PEARS. In 8 patients, an intervention was carried out after coronary
330 injury occurred (n=6) or for coronary impingement caused by the implant (n=2). While it may provide a
331 safety net, the most experienced PEARS surgeons consider operating without CPB preferable, preserving
332 normal anatomical relations rather than working on a collapsed heart. Avoidance of heparinisation allows
333 for a bloodless dissection of the ventriculo-aortic junction. It is recognised that manipulation of the
334 proximal coronary arteries is also a feature of root replacement, yet coronary complications are
335 uncommon after root replacement nowadays.[26,27] Both patients and surgeons must be aware of these
336 risks which reflect the learning curve of root surgery in patients with connective tissue disease.

337 In patients with no or trivial AR preoperatively, the observed changes in AR grade were subtle and
338 probably of limited clinical significance. In these patients, PEARS has the potential to stabilise AR by
339 fixing root dimensions.[5,6,9] For the majority of patients with mild AR preoperatively, it seems that
340 PEARS achieves a durable reduction of AR. While this makes sense from a mechanistic point of view –
341 reduction of root dimensions improves leaflet coaptation – long-term echocardiographic follow-up is

342 needed.[28] Importantly, as ExoVasc implants are scaled to aortic luminal diameter without including
343 wall thickness, even the 100% implant represents an undersizing.

344 There are several important limitations to this study. Because many patients were operated at an earlier
345 disease stage than at which root replacement is typically performed, long-term follow-up is needed to
346 monitor the occurrence of aortic events. While perioperative data was collected prospectively, follow-up
347 was retrieved retrospectively. 603 documented postoperative patient years represented 80% follow-up
348 completeness.[14] For patients with no or trivial AR preoperatively, we were unable to statistically
349 evaluate changes in AR grade over time because we could not differentiate true changes in AR from the
350 inter-observer variability of echocardiography in a multicentre study. Due to the limited number of
351 patients with AR $\geq 1/4$ and a follow-up echocardiography (n=37), it was not possible to determine
352 associations between patient characteristics or implant size (scaled to 95% or 100% diameter) and the
353 probability of having at least mild AR during follow-up. Furthermore, we are unable to compare our
354 observations with the natural evolution of MFS. While we did not study aortic diameters, PEARS has
355 previously shown to stabilise aortic root dimensions.[5,9,12]

356 **Conclusions**


357 This study represents the clinical history of a new surgical technique from patient 1 to 200. As PEARS
358 preserves the native aorta and aortic valve, earlier intervention in the disease progression is justifiable.
359 This suggests that the diameter threshold values in current guidelines do not accommodate many patients
360 who may benefit from PEARS. While operative mortality is low, the observed coronary complications
361 reflect the learning curve of root surgery in patients with connective tissue disease. No ascending aortic
362 dissections were observed in 596 postoperative patient years yet long-term follow-up is needed. PEARS
363 has the potential to stabilise or reduce AR, adding to its pre-emptive value and justifying the application
364 in patients with mild AR. PEARS provides an alternative for the treatment of aortic root aneurysm in the

365 hands of surgeons who are willing to train in its use and may be considered in well-informed patients in a
366 shared decision making process.


367 **Figures**

368

369




370 **Figure 1.** Illustration of the PEARS concept. A preoperative CT or MRI scan is used to create a model of
371 the patient's aorta, which is 3D-printed. A sleeve of polyethylene terephthalate mesh is shaped on this
372 former. The resulting ExoVasc is implanted around the patient's aorta, from the ventriculo-aortic junction
373 to the brachiocephalic artery. Postoperative imaging shows stable aortic dimensions and patent coronary
374 orifices at 16 years postoperatively in the first patient. Figure reproduced with permission.[6]



375


376 **Figure 2.** Flow chart of the first 200 patients operated on with the intention to perform PEARS for aortic
377 root aneurysm. 3 patients were lost to follow-up. FU=follow-up.

Survival and Survival free from reoperation



378

379 **Figure 3.** Kaplan-Meier estimates for survival and survival free from reoperation for all patients with
 380 postoperative follow-up, while also including the 1 perioperative death (n=197). The 3 patients lost to
 381 follow-up were excluded for this analysis. Dotted lines indicate 95% confidence intervals. Survival curves
 382 were truncated at 9 years postoperatively because, at this time, less than 10% of the initial population
 383 remains. SFFR=survival free from reoperation.



384

385 **Figure 4.** Evolution of AR grade over time for all patients with AR grade $\geq 1/4$ at the time of PEARS
 386 surgery (n=48). For 37 patients, one measurement of AR is available during follow-up. Each point
 387 corresponds to at least 1 patient/measurement at a certain time point. Patients with AR 2/4 preoperatively
 388 are shown in red. Patients with AR 0 and 0.5 are combined into 1 group.

389

390 Acknowledgments

391 The authors would like to thank all surgeons who performed PEARS operations (Andreas Hoschitzky, Ulrich
 392 Rosendahl, Mario Petrou, Fabio de Robertis, Massimo Caputo, Serban Stoica, Renzo Pessotto, Andrew McClean,
 393 Alastair Graham, Mark Redmond, Adam El Gamel, David Koolbergen, Mark Hazekamp, Jan Pirk, Ivo Skalski, Petr
 394 Kacer, Petr Santavy, Petr Nemecek, Pavel Zacek, John Chan, Peter Tesar, Nelson Alphonso, Prem Venugopal, Alistair
 395 Royse, Darryl Shore, David Anderson). We would also like to thank those who assisted in retrospective data
 396 collection (Radka Kockova, Beverley Horne, Lydie Tauchenova, Katie O’Sullivan, Yvonne May, Jessica Suna). We
 397 apologise if we have forgotten to mention anyone. We would like to thank Kevin Veen for the statistical support in
 398 modelling the evolution of aortic regurgitation after PEARS. The authors would like to thank the radiologists at the
 399 Royal Brompton Hospital (Raad Mohiaddin, Cemil Izgi, Michael Rubens and Tom Semple). Finally, we would like
 400 to thank the team at Exstent Ltd for their dedication to manufacturing ExoVasc implants.

401 **Funding statement**

402 LVH is supported by a Doctoral Grant Strategic Basic Research (SB 1S70220N) from the Research Foundation
403 Flanders (FWO). No additional funding to disclose.

404 **Conflict of Interest statement**

405 The only author with a potential conflict of interest is TG, the inventor of the ExoVasc device. He was the first
406 patient to undergo Personalised External Aortic Root Support (PEARS) surgery in 2004 and is a shareholder in
407 Exstent Ltd., the company that manufactures the PEARS ExoVasc device. Exstent Ltd holds a family of Patents and
408 Registered Trademarks covering the ExoVasc PEARS implant. All other authors have no conflict of interest to
409 disclose.

410 **Author Responsibility Information**

411 TG invented the procedure, developed the implant and was the first patient to undergo Personalised External Aortic
412 Root Support (PEARS) surgery. JRP performed the first 26 operations. CA is the lead surgeon and performed 45 of
413 the operations described in this study. This study was designed by LVH, TT, JRP, TG and FR. Perioperative data
414 was collected prospectively by TG as standard protocol for the reporting of device-related issues. Detailed in-
415 hospital outcomes and follow-up data were collected retrospectively by LVH, TT, JRP, CA and TG. Data analysis
416 was performed by LVH, FR, PV and JJMT with input from all co-authors. The first draft of the manuscript was
417 prepared by LVH, FR, PV and TT. All authors approved the final version to be published.

418

419 **Data availability statement**

420 The data underlying this article will be shared upon reasonable request to the corresponding author.

421 **References**

- 422 1 Radke RM, Baumgartner H. Diagnosis and treatment of Marfan syndrome: an update. *Heart*
423 2014;**100**:1382–91. doi:10.1136/heartjnl-2013-304709
- 424 2 Korteland NM, Etnel JRG, Arabkhani B, *et al.* Mechanical aortic valve replacement in non-elderly
425 adults: Meta-analysis and microsimulation. *Eur Heart J* 2017;**38**:3370–7.
426 doi:10.1093/eurheartj/ehx199
- 427 3 Flynn CD, Tian DH, Wilson-Smith A, *et al.* Systematic review and meta-analysis of surgical
428 outcomes in Marfan patients undergoing aortic root surgery by composite-valve graft or valve
429 sparing root replacement. *Ann Cardiothorac Surg* 2017;**6**:570–81. doi:10.21037/acs.2017.11.06
- 430 4 Bourguignon T, El Khoury R, Candolfi P, *et al.* Very long-term outcomes of the carpentier-
431 edwards perimount aortic valve in patients aged 60 or younger. *Ann Thorac Surg* 2015;**100**:853–9.
432 doi:10.1016/j.athoracsur.2015.03.105
- 433 5 Treasure T, Takkenberg JJM, Golesworthy T, *et al.* Personalised external aortic root support
434 (PEARS) in Marfan syndrome: analysis of 1-9 year outcomes by intention-to-treat in a cohort of
435 the first 30 consecutive patients to receive a novel tissue and valve-conserving procedure,
436 compared with the published. *Heart* 2014;**100**:969–75. doi:10.1136/heartjnl-2013-304913
- 437 6 Pepper J, Golesworthy T, Izgi C, *et al.* Personalised external aortic root support (PEARS) to
438 stabilise an aortic root aneurysm. *Br J Cardiol* 2020;**27**:87–92. doi:10.5837/bjc.2020.022
- 439 7 Pepper J, Golesworthy T, Utlely M, *et al.* Manufacturing and placing a bespoke support for the
440 Marfan aortic root: description of the method and technical results and status at one year for the
441 first ten patients. *Interact Cardiovasc Thorac Surg* 2010;**10**:360–5. doi:10.1510/icvts.2009.220319
- 442 8 Vanderveken E, Vastmans J, Claus P, *et al.* Mechano-biological adaptation of the pulmonary
443 artery exposed to systemic conditions. *Sci Rep* 2020;**10**:1–12. doi:10.1038/s41598-020-59554-7

- 444 9 Izgi C, Nyktari E, Alpendurada F, *et al.* Effect of personalized external aortic root support on
445 aortic root motion and distension in Marfan syndrome patients. *Int J Cardiol* 2015;**197**:154–60.
446 doi:10.1016/j.ijcard.2015.06.015
- 447 10 Van Hoof L, Verbrughe P, Verbeken E, *et al.* Support of the aortic wall : a histological study in
448 sheep comparing a macroporous mesh with low-porosity vascular graft of the same polyethylene
449 terephthalate material. *Interact Cardiovasc Thorac Surg* 2017;**25**:89–95. doi:10.1093/icvts/ivx009
- 450 11 Pepper J, Goddard M, Mohiaddin R, *et al.* Histology of a Marfan aorta 4.5 years after personalized
451 external aortic root support. *Eur J Cardio-Thoracic Surg* 2015;**48**:502–5. doi:10.1093/ejcts/ezu415
- 452 12 Izgi C, Newsome S, Alpendurada F, *et al.* External Aortic Root Support to Prevent Aortic
453 Dilatation in Patients With Marfan Syndrome. *J Am Coll Cardiol* 2018;**72**:1095–105.
454 doi:10.1016/j.jacc.2018.06.053
- 455 13 Vastmans J, Vancleef S, Vanderveken E, *et al.* Biomechanical evaluation of personalized external
456 aortic root support (PEARS): case- study. Presented at the GenTAC Aortic Summit 2020.
457 <https://www.youtube.com/watch?v=fiG2cWsBnb4>.
- 458 14 Von Allmen RS, Weiss S, Tevaearai HT, *et al.* Completeness of follow-up determines validity of
459 study findings: Results of a prospective repeated measures cohort study. *PLoS One* 2015;**10**:1–13.
460 doi:10.1371/journal.pone.0140817
- 461 15 Treasure T, Petrou M, Rosendahl U, *et al.* Personalized external aortic root support: a review of
462 the current status. *Eur J Cardio-Thoracic Surg* Published Online First: 2016.
463 doi:10.1093/ejcts/ezw078
- 464 16 Austin C, Thompson P, Fittipaldi M, *et al.* The consequences of incomplete covering of the critical
465 part of the aortic root in Personalized External Aortic Root Support. *Eur J Cardio-Thoracic Surg*
466 Published Online First: 2021. doi:10.1093/ejcts/ezab118

- 467 17 Treasure T, King A, Hidalgo Lemp L, *et al.* Developing a shared decision support framework for
468 aortic root surgery in Marfan syndrome. *Heart* 2018;**104**:480–6. doi:10.1136/heartjnl-2017-
469 311598
- 470 18 Nienaber CA, Yuan X, Ernst S. PEARS procedure and the difficulty to provide evidence for its
471 benefits. *Eur Heart J* 2020;**41**:4086–8. doi:10.1093/eurheartj/ehaa596
- 472 19 David TE, David CM, Manlhiot C, *et al.* Outcomes of Aortic Valve-Sparing Operations in Marfan
473 Syndrome. *J Am Coll Cardiol* 2015;**66**:1445–53. doi:10.1016/j.jacc.2015.07.041
- 474 20 Price J, Magruder JT, Young A, *et al.* Long-term outcomes of aortic root operations for Marfan
475 syndrome: A comparison of Bentall versus aortic valve-sparing procedures Read at the 95th
476 Annual Meeting of the American Association for Thoracic Surgery, Seattle, Washington, April 25-
477 29, 2015. *J Thorac Cardiovasc Surg* 2016;**151**:330–8. doi:10.1016/j.jtcvs.2015.10.068
- 478 21 Schoenhoff FS, Langhammer B, Wustmann K, *et al.* Decision-making in aortic root surgery in
479 Marfan syndrome: Bleeding, thromboembolism and risk of reintervention after valve-sparing or
480 mechanical aortic root replacement. *Eur J Cardio-thoracic Surg* 2015;**48**:931–6.
481 doi:10.1093/ejcts/ezu553
- 482 22 Silverman DI, Burton KJ, Gray J, *et al.* Life expectancy in the Marfan syndrome. *Am J Cardiol*
483 1995;**75**:157–60. doi:10.1016/S0002-9149(00)80066-1
- 484 23 Cañadas V, Vilacosta I, Bruna I, *et al.* Marfan syndrome. Part 1: pathophysiology and diagnosis.
485 *Nat Rev Cardiol* 2010;**7**:256–65. doi:10.1038/nrcardio.2010.30
- 486 24 Adriaans BP, Wildberger JE, Westenberg JJM, *et al.* Predictive imaging for thoracic aortic
487 dissection and rupture: moving beyond diameters. *Eur Radiol* 2019;**29**:6396–404.
488 doi:10.1007/s00330-019-06320-7

- 489 25 Groth KA, Stochholm K, Hove H, *et al.* Aortic events in a nationwide Marfan syndrome cohort.
490 *Clin Res Cardiol* 2017;**106**:105–12. doi:10.1007/s00392-016-1028-3
- 491 26 de Heer F, Kluin J, Elkhoury G, *et al.* AVIATOR: An open international registry to evaluate
492 medical and surgical outcomes of aortic valve insufficiency and ascending aorta aneurysm. *J*
493 *Thorac Cardiovasc Surg* 2019;**157**:2202-2211.e7. doi:10.1016/j.jtcvs.2018.10.076
- 494 27 Coselli JS, Volguina I V., Lemaire SA, *et al.* Early and 1-year outcomes of aortic root surgery in
495 patients with Marfan syndrome: A prospective, multicenter, comparative study. *J Thorac*
496 *Cardiovasc Surg* 2014;**147**:1758-1767.e4. doi:10.1016/j.jtcvs.2014.02.021
- 497 28 Plonek T, Dumanski A, Obremaska M, *et al.* First beating-heart valve-sparing aortic root repair: A
498 ‘corset’ technique. *Ann Thorac Surg* 2015;**99**:1464–6. doi:10.1016/j.athoracsur.2014.11.062
- 499